Antibody Libraries

Antibody Discovery

Specifica

Specifica, a Q2 Solutions Company, develops and delivers exceptional antibody libraries to support drug discovery. Our patented Generation 3 platform yields drug-like antibodies directly from selections, minimizing the need for downstream affinity and biophysical engineering.

Specifica antibody libraries deliver:

 

specifica-gen3-library-platform_v2

 

Learn about our key Antibody Discovery services:

 

Fast Discovery

Specifica provides high affinity antibodies with excellent developability and high diversity, saving time and money during development.

 

High Affinity

  • 60% of antibodies from platform have affinities below 10nM
  • 20% are in the sub-nanomolar range
  • Excluding pMHC selections, more than 75% of campaigns generate at least 1 sub-nanomolar antibody

 

High Diversity

  • AbXtract machine learning module groups antibodies into 10 to 1,000 distinct clusters
  • Provides antibodies against a wide variety of target epitopes with the potential for differential biology


Developability

  • Sequence liabilities are purged from all CDRs except HCDR3
  • More than 80% of antibodies have no measurable biophysical liabilities
  • Our antibodies behave as well as the best therapeutic antibodies

Related Thought Leaders Insights


Validation of a Stem Cell Assay Used as a Key Efficacy Marker for FDA Approval

Presented at CYTO 2024, the 37th annual Congress of the International Society for the Advancement of Cytometry, May 5-8, 2024 The recent announcement by BiolineRx of the FDA approval of APHEXDA™...

Anti-Drug Antibody (ADA) Assay for Xpro 1595, A Self-Assembling Trimer: Alternative to Standard Bridging Approach

Presented at WRIB 2024 by Jing Liu, Principle Scientist, this poster looks at the challenges posed by XPro1595, a pegylated, engineered form of soluble human Tumor Necrosis Factor alpha (TNF alpha)...

Development of a Multi-biomarker Assay for Serum Proteins by the Prognostic Lung Fibrosis Consortium (PROLIFIC)

Rules-Based Medicine, a Q2 Solutions company, was featured in a posted presented at the American Thoracic Society’s annual meeting in May 2024. The poster—Development of a Multi-biomarker Assay for...